<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934904</url>
  </required_header>
  <id_info>
    <org_study_id>2020-KY-032-03</org_study_id>
    <nct_id>NCT04934904</nct_id>
  </id_info>
  <brief_title>The Treatment of Acute Gastrointestinal Injury Via Ultrasound-guided Erector Spinae Plane Block</brief_title>
  <official_title>The Treatment of Acute Gastrointestinal Injury Via Ultrasound-guided Erector Spinae Plane Block - a Prospective, Single-center, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this single-center, randomized, parallel control clinical trial, patients will be randomly&#xD;
      assigned to two groups. The treatment group receives ultrasound-guided erector spinae plane&#xD;
      block with routine treatment of Acute Gastrointestinal Injury (AGI) for 7 days or until&#xD;
      transferred to the general ward, while the control group only receives routine treatment of&#xD;
      AGI. The primary outcome is the cure and remission rate of AGI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:&#xD;
&#xD;
      Study title: The treatment of Acute Gastrointestinal Injury via ultrasound-guided erector&#xD;
      spinae plane block - a prospective, single-center, randomized, controlled trial&#xD;
&#xD;
      Principal Investigator: Professor Wang Hua, Department of Critical Care Unit, Zhujiang&#xD;
      Hospital of Southern Medical University&#xD;
&#xD;
      Study subjects: Patients age from 18 to 80 with AGI â…¡ or greater&#xD;
&#xD;
      Study phase: Investigator Initiated Trial(IIT)&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
      To evaluate whether ultrasound-guided erector spinae plane block can reduce the grade of AGI&#xD;
      , and improve the cure and remission rate of AGI.&#xD;
&#xD;
      Experimental Group:&#xD;
&#xD;
      On the basis of routine clinical treatment, the ultrasound-guided erector spinae plane block&#xD;
      intervention is given. On the first day enrolled, patients are performed with&#xD;
      ultrasound-guided erector spinae plane block and cannula will be placed on T8 bilaterally.&#xD;
      0.375% ropivacaine of 20ml is injected separately to both sides with 2ml per hour. Injection&#xD;
      is performed twice a day for 7 days or until transferred to the general ward.&#xD;
&#xD;
      Controlled Group:&#xD;
&#xD;
      The patients will receive the clinical routine treatment according of AGI recommended by the&#xD;
      2012 European Society of Critical Care Medicine guidelines, with a uniform nutritional&#xD;
      strategy(gastrointestinal dynamic drugs, traditional Chinese drugs and physical&#xD;
      rehabilitation therapy).&#xD;
&#xD;
      Course: 7 days Sample size: 100 Sites: 1&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
        1. the cure rate of AGI on the seventh day&#xD;
&#xD;
        2. the remission rate of AGI on the seventh day&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        1. Scores:&#xD;
&#xD;
        2. Gastrointestinal function indicators:&#xD;
&#xD;
        3. The inflammatory indicators:&#xD;
&#xD;
        4. the lactic acid(Lac)&#xD;
&#xD;
        5. cross-sectional area of pyloric antrum(AS) with ultrasound&#xD;
&#xD;
        6. width of the colons with abdominal X ray or CT&#xD;
&#xD;
        7. the 28-day mortality&#xD;
&#xD;
        8. gastrointestinal dysfunction and duration (GIF)&#xD;
&#xD;
      Additional endpoints:&#xD;
&#xD;
        1. The length of stay in ICU&#xD;
&#xD;
        2. The total cost of ICU hospitalization&#xD;
&#xD;
        3. The total days of hospitalization&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental Group:&#xD;
On the basis of the clinical routine treatment of AGI in severe patients (gastrointestinal dynamic drugs, traditional Chinese drugs and physical rehabilitation therapy), the ultrasound-guided erector spinae plane block intervention is given.&#xD;
Controlled Group:&#xD;
Normal Treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This study adopted a randomized, open, blank control design, and did not blind researchers, patients or clinicians.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the cure rate of AGI</measure>
    <time_frame>Day at 7</time_frame>
    <description>the cure rate of AGI on the seventh day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the remission rate of AGI</measure>
    <time_frame>Day at 7</time_frame>
    <description>the remission rate of AGI on the seventh day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Physiology and Chronic Health Evaluation(APACHE II)</measure>
    <time_frame>on the included day(within 24 hours)</time_frame>
    <description>measuring endpoints include:&#xD;
body temperature&#xD;
mean arterial pressure (MAP)&#xD;
heart rate (HR)&#xD;
respiratory rate (RR)&#xD;
fraction of inspiration O2 (FIO2)&#xD;
potential of hydrogen (PH)&#xD;
Na+&#xD;
K+&#xD;
serum creatinine (SCr)&#xD;
hematocrit (Hct%)&#xD;
white blood cell (WBC)&#xD;
Age&#xD;
immunosuppression before/after surgery or serious organ dysfunction&#xD;
(Higher score means a worse outcome.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>SOFA score evaluate status of the following organ systems separately:&#xD;
(Higher score means a worse outcome.)&#xD;
Respiration Partial Pressure of Oxygen/Fraction of Inspiration O2 (PaO2/FiO2)&#xD;
Coagulation Platelets&#xD;
Liver Bilirubin&#xD;
Circulatory Mean arterial pressure&#xD;
Central Nervous System Glasgow coma score&#xD;
Renal Creatinine (or urine output)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the intraperitoneal pressure(IAP)</measure>
    <time_frame>on the day 0,1,2,3 and 7</time_frame>
    <description>Gastrointestinal function indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal perfusion pressure(AAP)</measure>
    <time_frame>on the day 0,1,2,3 and 7</time_frame>
    <description>Gastrointestinal function indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total gastric residual volume(GRVs)</measure>
    <time_frame>on the day 0,1,2,3 and 7</time_frame>
    <description>Gastrointestinal function indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>feeding dose</measure>
    <time_frame>on the day 0,1,2,3 and 7</time_frame>
    <description>Gastrointestinal function indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6(IL-6)</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>The inflammatory indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cell(WBC)</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>The inflammatory indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte (LYM)</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>The inflammatory indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutral Granular Cell(NEUT)</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>The inflammatory indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin (PCT)</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>The inflammatory indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypersensitive C Reactive Protein(HSCRP)</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>The inflammatory indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lactic acid(Lac)</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>the serum level of the lactic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-sectional area of pyloric antrum(AS)</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>cross-sectional area of pyloric antrum(AS) with ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Width of the colons</measure>
    <time_frame>on the day 0,1,3 and 7</time_frame>
    <description>width of the colons with abdominal X ray or CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 28-day mortality</measure>
    <time_frame>on 28 days or the termination date</time_frame>
    <description>the 28-day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal dysfunction and duration(GIF)</measure>
    <time_frame>on the day 1,2,3 and 7</time_frame>
    <description>fasting(score 1 point)&#xD;
reflux(score 2 points)&#xD;
gastrointestinal decompression(1 point)&#xD;
Gastric retention(2 points)&#xD;
abdominal distension(2 points)&#xD;
abdominal pain(2 points)&#xD;
diarrhea(2 points)&#xD;
hypoactive bowel sounds(1 point)&#xD;
bowel sounds disappear(2 points)&#xD;
constipation(2 points)&#xD;
The mentioned indicators will be combined to report GIF in score.&#xD;
Grade 0 (Normal) : 0 score&#xD;
Grade 1 (Mild) : 1~4 score&#xD;
Grade 2 (Medium) : 5~9 score&#xD;
Grade 3 (Serious) : &gt;10 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of stay in ICU</measure>
    <time_frame>through study completion, from 7 to 28 days.</time_frame>
    <description>Additional endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total cost of ICU hospitalization</measure>
    <time_frame>through study completion, from 7 to 28 days</time_frame>
    <description>Additional endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total days of hospitalization</measure>
    <time_frame>through study completion, from 7 to 28 days</time_frame>
    <description>Additional endpoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastrointestinal Disease</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the basis of the clinical routine treatment of AGI in severe patients, the Experimental Group will receives ultrasound-guided erector spinae plane block with routine treatment of AGI for 7 days or until transferring to the general ward.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>the routine clinical treatment of AGI is given to severe patients, such as gastrointestinal dynamic drugs, traditional Chinese drugs and physical rehabilitation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine injection</intervention_name>
    <description>On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>ropivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. AGI are diagnosed according to the diagnostic criteria proposed by European Society&#xD;
             Intensive Care Medicine (ESICM) in 2012 and the AGI grade great than or equal to II.&#xD;
&#xD;
          2. Age 18-80 years.&#xD;
&#xD;
          3. Expected length of stay longer than 3 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mean arterial pressure is still less than 65 millimeter of Mercury (mmHg) treated with&#xD;
             rehydration and vasoactive agents, or with the dosage of norepinephrine more than&#xD;
             0.5ug/kg/min.&#xD;
&#xD;
          2. Heart rates are less than 50 beats per minute or moderate and severe atrioventricular&#xD;
             block without pacemaker.&#xD;
&#xD;
          3. Primary gastrointestinal disease such as mechanical intestinal obstruction, massive&#xD;
             hemorrhage of gastrointestinal tract and gastrointestinal perforation.&#xD;
&#xD;
          4. Severe trauma of chest, abdomen or back. gastrointestinal tract surgery history.&#xD;
&#xD;
          5. Neuromuscular disorders.&#xD;
&#xD;
          6. Drug addiction, alcohol abuse, opioid or amphetamine dependence, or mental disorders.&#xD;
&#xD;
          7. Pregnancy.&#xD;
&#xD;
          8. Brain dead.&#xD;
&#xD;
          9. Malignant tumor, or end-stage cachexia.&#xD;
&#xD;
         10. With contraindications of the erector spinae plane block (ESPB), such as local&#xD;
             infection, Spinal diseases or immobilization.&#xD;
&#xD;
         11. Allergy to local anesthetics.&#xD;
&#xD;
         12. Significant abnormalities in blood coagulation parameters.&#xD;
&#xD;
         13. Without written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Wang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Cai</last_name>
    <phone>+86-62782927</phone>
    <email>caijing78@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Wang, MD,PhD</last_name>
    <phone>+86-62782927</phone>
    <email>icuwanghua@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510280</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Cai</last_name>
      <phone>+86-62782927</phone>
      <email>caijing78@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hua Wang, MD,PhD</last_name>
      <phone>+86-62782927</phone>
      <email>icuwanghua@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute gastrointestinal injury</keyword>
  <keyword>Erector spinal muscle plane block</keyword>
  <keyword>Ropivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

